

1 *Changes in Chemosensory Sensation during COVID-19*

2

3 ORIGINAL CONTRIBUTION

4

5 Smell, taste and chemesthesis disorders in patients with the SARS-CoV-2
6 Omicron variant in China

7

8 Ying Chen^{1,†}, Yuying Chen^{1,†}, Xiang Liu², Chao Yan³, Laiquan Zou^{1,*}

9

10 ¹ Chemical Senses and Mental Health Lab, Department of Psychology, School of Public Health,
11 Southern Medical University, Guangzhou, Guangdong, China

12 ² Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
13 Guangdong, China

14 ³ Key Laboratory of Brain Functional Genomics (MOE & STCSM), Shanghai Changning-ECNU
15 Mental Health Center, School of Psychology and Cognitive Science, East China Normal University,
16 Shanghai, China

17 * Correspondence: zoulq@smu.edu.cn; Tel.: +86-20-62789234

18 † These authors contributed equally to this work.

19 Main text word count: 2336 words

20

21 SUMMARY

22 **Background:** *Chemosensory disorders (including smell, taste and chemesthesis) are*
23 *among the established symptoms of COVID-19 infection; however, new data indicate*
24 *that the changes in chemosensory sensation caused by COVID-19 may differ among*
25 *populations and COVID-19 variants. To date, few studies have focused on the*
26 *influence of the SARS-CoV-2 Omicron variant on qualitative changes and quantitative*
27 *reductions in chemosensory function in China.*

28 **Methodology:** *We conducted a cross-sectional study of patients with COVID-19*
29 *caused by the Omicron variant, to investigate the prevalence of chemosensory*
30 *disorders and chemosensory function before and during infection, using an online*
31 *questionnaire.*

32 **Results:** *A total of 1245 patients with COVID-19 completed the survey. The*
33 *prevalence rates of smell, taste, and chemesthesis disorders were 69.2%, 67.7%, and*
34 *31.4%, respectively. Our data indicate that sex, age, smoking, and COVID-19-related*
35 *symptoms, such as lack of appetite, dyspnea, and fatigue, may be associated with*
36 *chemosensory disorders during COVID-19.*

37 **Conclusions:** *Self-rating of chemosensory function revealed that patients experienced*
38 *a general decline in smell, taste, and chemesthesis function. Further longitudinal*
39 *research studies are needed to generate additional data based on objective*
40 *assessment and investigate the factors influencing chemosensory function in COVID-*
41 *19.*

42

43 *Key words: chemosensory, COVID-19, cross-sectional studies, Omicron, prevalence*

44

45 INTRODUCTION

46 Coronavirus disease 2019 (COVID-19) was first detected in Wuhan in December
47 2019, and rapidly spread throughout more than 80 countries^(1,2). Information from the
48 World Health Organization shows that the number of confirmed COVID-19 cases was
49 756,411,740 by 16 February, 2023 (<https://covid19.who.int>). There are reports that
50 chemosensory disorders are important symptoms of COVID-19 infection⁽³⁻⁵⁾. Studies
51 from the United States, Europe, Malaysia, and Singapore demonstrated that 12%–

52 88% of COVID-19-infected patients have olfactory and taste disorders^(4,6-8), while
53 studies from China reported that 5%–25% of patients have smell and/or taste disorder
54^(9,10). The Omicron variant of SARS-CoV-2 was first detected in South Africa in
55 November 2021, and became the main epidemic strain in the world by 15 January
56 2022^(11,12). Some studies have found that the Omicron variant causes less smell and
57 taste dysfunction than non-Omicron SARS-CoV-2⁽¹³⁻¹⁵⁾. Further, a meta-analysis
58 found that the prevalence rates of olfactory dysfunction caused by the Omicron
59 variant are 8%–17% and 2%–17% the in UK and USA, respectively⁽¹⁵⁾.

60 In China, the prevalence of olfactory dysfunction caused by the Omicron variant is
61 reported as 0–9%⁽¹⁶⁻²⁰⁾; however, the sample sizes of studies to date have been
62 relatively small and researchers have focused on patient characteristics and clinical
63 symptoms, with insufficient discussion of chemosensory changes.

64 Chemosensory sensation (including smell, taste, and chemesthesis) have important
65 roles in sensing potential threats, such as toxins, bacteria, and chemical irritants⁽²¹⁾,
66 but most relevant studies have focused solely on smell and taste, and ignored
67 chemesthesis, which is defined as detection of burning, cooling, or tingling in the
68 mouth^(5,21). Since these three systems are independent sensory systems, with distinct
69 peripheral and central neural mechanisms⁽²²⁾, it is necessary to explore the influence
70 of COVID-19 on these three senses separately. Further, chemosensory disturbances
71 can result in qualitative changes or quantitative reductions in smell or taste, associated
72 with different mechanisms. Qualitative changes include parosmia (things smell
73 different from usual), phantosmia (hallucination of olfactory senses), smell
74 fluctuation, parageusia (distorted taste sensations) and phantogeusia (hallucination of
75 gustatory senses). Quantitative reductions include anosmia (complete loss of
76 olfaction), hyposmia (partial loss of olfaction), ageusia (loss of all or specific
77 gustatory senses) and hypogeusia (reduced ability to taste things)^(23,24). Previous
78 studies have generally explored changes or reductions of smell and taste, but have
79 rarely classified patient conditions according to the qualitative of the disorders.

80 There is a pressing need to conduct a cross-sectional study to assess the effects of
81 Omicron on patient smell, taste, and chemesthesis in China. The primary aim of this
82 study was to investigate the prevalence of chemosensory disorders, as well as
83 qualitative and quantitative changes of the chemosensory senses during Omicron
84 infection. A secondary aim was to identify factors associated with chemosensory
85 disorders, including sex, age, alcohol intake, chronic rhinitis, allergic rhinitis, and
86 comorbidity or specific conditions, as well as COVID-19 related characteristics.

87

88 MATERIALS AND METHODS

89 *Participants*

90 Participants answered questions in an online survey about their sociodemographic
91 characteristics, COVID-19 infection status, and smell, taste, and chemesthesis
92 between 20 December 2022 and 20 January 2023. A total of 1311 patients (all aged \geq
93 18 years) recovered from COVID-19 were invited to participate in the survey.
94 Participants who did not answer all of the questions or failed to pass the lie test were
95 excluded. The final sample consisted of 1245 participants: 983 women (79.0%) and
96 262 men (21.0%), with a mean \pm standard deviation (SD) age of 25.45 ± 6.57 years
97 old. As this was a cross-sectional study, a 0.95 power estimate, an effect size of 0.3,
98 and an α value of 0.05 were used to calculate the necessary sample size in the
99 G*Power program⁽²⁵⁾. The sample size in our study was far larger than the result
100 proposed by the G*Power program. All participants read an informed consent form
101 and agreed to the use of their data for research. This study received ethics approval

102 from the Ethics Committee of Southern Medical University.

103

104 *Data collection*

105 A self-administered questionnaire was used to survey patients who had recovered
106 from COVID-19 in China. The questionnaire was adapted from existing online
107 questionnaires developed by the Global Consortium for Chemosensory Research
108 (GCCR)⁽⁵⁾. The GCCR core questionnaire has been implemented in 10 languages as
109 of April 18, 2020, and used or adapted in many other research studies^(4,26,27). Data
110 collected included demographic information, COVID-19-related characteristics, and
111 patient chemosensory situations, before and during infection. To study the sense of
112 smell and taste in further detail, smell situation options included anosmia, hyposmia,
113 parosmia, phantosmia, and smell fluctuation, and taste situation options included
114 ageusia, hypogeusia, parageusia, and phantogeusia^(5,24).

115

116 *Statistical analysis*

117 Associations between categorical variables were tested using the Chi-Square test.
118 Self-ratings of smell, taste, and chemesthesis before and during COVID-19 diagnosis
119 were evaluated using the Wilcoxon matched pairs signed-rank test. Statistical
120 significance was set at $p < 0.05$ and all reported p values are two-tailed. All statistical
121 analyses were performed using IBM SPSS Statistics (SPSS, version 22).

122

123 RESULTS

124 *General prevalence*

125 Of 1245 patients infected with COVID-19, 69.2% (861/1245) reported having smell
126 disorder, 67.7% (843/1245) reported having taste disorder, and 31.4% (391/1245)
127 reported chemesthesis disorder (Table 1); the prevalence rates of specific types of
128 smell and taste disorder are also shown in Table 1. Among patients who experienced
129 anosmia or hyposmia ($n = 819$), only 12.3% (101/819) reported that the anosmia or
130 hyposmia was completely caused by nasal congestion. Further, 56.9% (708/1245) of
131 patients reported loss of both smell and taste, 12.3% (153/1245) reported loss of smell
132 only, and 10.8% (135/1245) reported loss of taste only.

133

134 *Smell disorder*

135 The data presented in Table 2 show that there was a statistically significant difference
136 in smoking status between patients with and without smell disorder ($p < 0.05$); where
137 smell disorder was significantly more common among patients who were current or
138 former smokers ($p < 0.05$). No statistically significant differences in other
139 demographic characteristics, including sex, age group, alcohol intake, chronic rhinitis,
140 allergic rhinitis, and comorbidity or special condition, were found between patients
141 with and without smell disorder (all $p > 0.05$). Significant differences in rehabilitation
142 status, COVID-19-related symptoms (lack of appetite, dry and sore throat, myalgia,
143 stuffy/running nose, dyspnea and fatigue), and COVID-19 vaccination status, were
144 also observed between patients with and without smell disorder (all $p < 0.05$). Chi-
145 square analysis indicated that patients with symptoms including lack of appetite, dry
146 and sore throat, myalgia, stuffy/running nose, dyspnea, and fatigue, were prone to
147 having smell disorder. Further, patients who did not undergo COVID-19 vaccination
148 were more likely to experience smell disorder ($p < 0.05$). Associations between
149 specific types of smell disorder (anosmia, hyposmia, parosmia, phantosmia, and
150 olfactory fluctuation) and demographic/COVID-19-related characteristics are
151 presented in the supplemental material (Table S1–S5).

152 Only 4.8% (60/1245) of patients reported parosmia, while 7.9% (98/1245) reported
153 phantosmia. Pleasantness rating score on 100-point scale of the distorted smell caused
154 by parosmia was 25.72 ± 24.81 (Mean \pm SD), and that of phantom smells was $26.74 \pm$
155 25.98 (Mean \pm SD). Parosmic individuals mostly reported smells of food (e.g., meat,
156 rice, or soup) or other daily necessities (e.g., toothpaste, shampoo, or liquid detergent)
157 that became roasted, burnt, or spoiled (e.g., “The smell of chicken soup turned to
158 burning”). In phantomic individuals, the most frequently reported phantom smells
159 were smoky, burnt, and rotten.

160 Patients rated their smell function before and during COVID-19 on a 100-point scale.
161 Compared to scores before COVID-19 (88.53 ± 13.24 , Mean \pm SD), those during
162 COVID-19 (52.38 ± 32.83 , Mean \pm SD) were significantly lower ($t = 38.386$, $p <$
163 0.001) (Figure 1).

164

165 *Taste disorder*

166 There were no statistically significant differences in demographic characteristics, such
167 as sex, age group, and smoking/alcohol intake, between patients with and without
168 taste disorder (all $p > 0.05$, Table 3). Patients with COVID-19-related symptoms, such
169 as lack of appetite, dry and sore throat, myalgia, headache, diarrhea,
170 cough/expectoration, stuffy/running nose, dyspnea, and fatigue had a significant
171 chance of experiencing taste disorder (all $p < 0.05$). Associations between specific
172 types of taste disorder (ageusia, hypogeusia, parageusia, phantogeusia) and
173 demographic/COVID-19-related characteristics are detailed in the supplemental
174 material (Table S6–S9). Additionally, of patients with total loss or decrease of
175 specific taste ($n = 597$), 36.9% (220/597) reported total loss or decrease in the taste of
176 sour, 45.9% (274/597) of sweet, 20.1% (120/597) of bitter, 51.4% (307/597) of salty,
177 and 71.9% (429/597) of umami.

178 Parageusia was described in 22.7% (282/1245) of patients, while phantogeusia was
179 identified in 26.7% (333/1245) of patients. Pleasantness rating score on 100-point
180 scale of the distorted gustatory sense caused by parosmia was 19.80 ± 21.33 (Mean \pm
181 SD), while that for gustatory hallucination was 24.97 ± 34.38 (Mean \pm SD). Most
182 patients with parageusia described that the flavors of foods, such as orange, meat, or
183 candy, became bitter (e.g., “The rice has turned bitter”). Patients with phantogeusia
184 most frequently reported a constant bitter flavor, without anything in mouth.

185 Similar to smell, patients rated their taste function before and during COVID-19. The
186 score during COVID-19 (58.78 ± 29.74 , Mean \pm SD) was significantly lower than that
187 before COVID-19 (90.13 ± 11.60 , Mean \pm SD) ($t = 37.173$, $p < 0.001$).

188

189 *Chemesthesis disorder*

190 No significant differences in demographic characteristics, including sex, age group,
191 smoking and alcohol intake, chronic rhinitis, allergic rhinitis, and any comorbidity or
192 special condition, were found between patients with and without chemesthesis
193 disorder (all $p > 0.05$, Table 4). Significant differences in COVID-19-related
194 symptoms (lack of appetite, dyspnea, and fatigue) were detected between patients
195 with and without chemesthesis disorder (all $p < 0.05$).

196 Patients also rated their chemesthesis function before and during COVID-19. The
197 score during COVID-19 (71.82 ± 26.48 , Mean \pm SD) was also significantly lower
198 than that before COVID-19 (88.50 ± 15.83 , Mean \pm SD) ($t = 24.700$, $p < 0.001$).

199

200 DISCUSSION

201 In the current study, we found that the prevalence rates of smell, taste, and

202 chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron
203 variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Previous studies
204 reported prevalence rates of olfactory dysfunction ranging from 3.2% to 98.3% and of
205 taste dysfunction ranging from 5.6% to 62.7%^(28,29). Previous research has found that
206 the reported prevalence of smell, taste, and chemesthesis disorder varies according to
207 differences in population, assessment method, and virus strain⁽²⁸⁾. A meta-analysis
208 based on data from 24 studies, including over 8400 participants from 13 countries,
209 found the pooled prevalence rates of patients with smell and taste dysfunction were
210 41.0% and 38.2%, respectively⁽²⁹⁾. Another meta-analysis involving 18 studies
211 showed that the prevalence of alteration of the sense of smell or taste was 47%⁽³⁰⁾.
212 Importantly, recent studies have focused primarily on quantitative changes in smell
213 and taste, while qualitative changes of smell and taste were not addressed^(29,31–33);
214 however, we included five types of smell disorder (anosmia, hyposmia, parosmia,
215 phantosmia and olfactory fluctuation), and four types of taste disorder (ageusia,
216 hypogeusia, parageusia, phantogeusia) in our study. The prevalence of anosmia in our
217 study was 23.3%, that of hyposmia was 42.5%, ageusia was 19.0%, and hypogeusia
218 was 40.1%. Studies have also found that the prevalence of smell and taste disorder
219 decreased during the period of Omicron variant dominance, but remained more than
220 30%, similar to our findings^(28,34).

221 Males are reported to be more prone to loss of smell and taste senses than females⁽³⁵⁾;
222 however, our data demonstrate that females were more prone to complete loss of
223 olfaction, similar to the findings of Lechien et al.^(6,8). In terms of taste loss, we did
224 not detect significant differences between the sexes, similar to Al-Rawi et al.^(3,36).
225 Further, Al-Rawi et al. found more significant smell and taste loss among individuals
226 in their late 30s⁽³⁾, consistent with our finding that patients aged 30–39 years are more
227 prone to anosmia and ageusia. Previous research showed that smokers are more
228 vulnerable to anosmia and ageusia⁽³⁵⁾; however, we detected no significant
229 differences between smokers and non-smokers in terms of anosmia and ageusia in our
230 study. Interestingly, we found that smoking had adverse effects on smell disorders in
231 general.

232 We also found that some COVID-19 related symptoms, such as lack of appetite,
233 dyspnea, and fatigue, were associated with chemosensory disorder rates. Associations
234 of these factors with chemosensory disorders have been reported in previous research
235^(7,8); however, whether they are risk factors for chemosensory disorders requires
236 further study.

237 In the current study, we report the prevalence, quality, and quantity of chemosensory
238 changes in patients infected with the Omicron variant in China. Patients often confuse
239 chemesthesis with smell and taste when self-reporting, thus our survey included an
240 expanded section relating to chemesthesis, with the aim of better distinguishing the
241 influences of COVID-19 infection on smell, taste and chemesthesis. We also made
242 detailed distinctions among the quality and quantity of changes in smell and taste, and
243 found that these changes differed in the COVID-19 infected population, which may
244 provide reference data for the follow-up research on the mechanism underlying
245 COVID-19 influence on smell and taste. Moreover, we expanded the Chinese version
246 of the GCCR core questionnaire, to provide reference data for future domestic
247 research.

248 Our study also had several limitations. First, the participants were mostly from the
249 southern areas of China. Second, the collection of the data for our study was based on
250 self-report, which may lead to confirmation bias of chemosensory disorders.
251 Additional objective assessment of chemosensory disorders is needed in future

252 studies. Third, our study was cross-sectional, and longitudinal studies are needed to
253 determine the direction of associations among variables in our study.
254 In conclusion, the current study found that the prevalence rates of smell, taste, and
255 chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron
256 variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Patients experienced
257 a general decline in the function of smell, taste, and chemesthesis. Sex, age, smoking,
258 and COVID-19-related symptoms, such as lack of appetite, dyspnea, and fatigue, may
259 be associated with chemosensory disorders during COVID-19. The present study
260 contributes to existing knowledge of chemosensory disorders in COVID-19 by
261 providing Chinese data collected during Omicron variant dominance.

262

263 ACKNOWLEDGEMENTS

264 We thank all the participants who participated in our study.

265

266 AUTHORSHIP CONTRIBUTION

267 Conceptualization, Laiquan Zou; formal analysis, Ying Chen, Yuying Chen, and
268 Laiquan Zou; investigation, Ying Chen, Yuying Chen, Xiang Liu, Chao Yan, and
269 Laiquan Zou; writing—original draft, Ying Chen, Yuying Chen, and Laiquan Zou;
270 writing—review & editing, Xiang Liu, Chao Yan, and Laiquan Zou. All authors have
271 read and agreed to the published version of the manuscript.

272

273 CONFLICT OF INTEREST

274 The authors declare that they have no competing interests.

275

276 FUNDING

277 None.

278

279 REFERENCES

280

- 281 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
282 Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727–33.
- 283 2. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease
284 2019 in China. *N Engl J Med.* 2020;382(18):1708–20.
- 285 3. Al-Rawi NH, Sammouda AR, AlRahin EA, et al. Prevalence of Anosmia or
286 Ageusia in Patients With COVID-19 Among United Arab Emirates Population.
287 *Int Dent J.* 2022;72(2):249–56.
- 288 4. Lee S-H, Yeoh ZX, Sachlin IS, et al. Self-reported symptom study of COVID-
289 19 chemosensory dysfunction in Malaysia. *Sci Rep.* 2022;12(1):2111.
- 290 5. Parma V, Ohla K, Veldhuizen MG, et al. More Than Smell—COVID-19 Is
291 Associated With Severe Impairment of Smell, Taste, and Chemesthesis. *Chem*
292 *Senses.* 2020;45(7):609–22.
- 293 6. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory
294 dysfunctions as a clinical presentation of mild-to-moderate forms of the
295 coronavirus disease (COVID-19): a multicenter European study. *Eur Arch*
296 *Otorhinolaryngol.* 2020;277(8):2251–61.
- 297 7. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported
298 symptoms to predict potential COVID-19. *Nat Med.* 2020;26(7):1037–40.
- 299 8. Tham AC, Thein T-L, Lee CS, et al. Olfactory taste disorder as a presenting
300 symptom of COVID-19: a large single-center Singapore study. *Eur Arch*
301 *Otorhinolaryngol.* 2021;278(6):1853–62.

- 302 9. Song J, Deng Y, Wang H, et al. Self-reported Taste and Smell Disorders in
303 Patients with COVID-19: Distinct Features in China. 2021;
- 304 10. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized
305 Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.*
306 2020;77(6):683.
- 307 11. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and
308 risk of hospital admission in individuals infected with SARS-CoV-2 during
309 periods of omicron and delta variant dominance: a prospective observational
310 study from the ZOE COVID Study. *The Lancet.* 2022;399(10335):1618–24.
- 311 12. Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2
312 variant of concern Omicron. *Cell Mol Immunol.* 2022;19(2):293–5.
- 313 13. Chee J, Chern B, Loh WS, Mullol J, Wang DY. Pathophysiology of SARS-
314 CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical
315 Impact. *Curr Allergy Asthma Rep.* 2023;23(2):121–31.
- 316 14. Rodriguez-Sevilla JJ, Güerri-Fernández R, Bertran Recasens B. Is There Less
317 Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant
318 Infection? *Front Med.* 2022;9:852998.
- 319 15. von Bartheld CS, Wang L. Prevalence of Olfactory Dysfunction with the
320 Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis.
321 *Cells.* 2023;12(3):430.
- 322 16. Li Q, Liu X, Li L, et al. Comparison of clinical characteristics between SARS-
323 CoV-2 Omicron variant and Delta variant infections in China. *Front Med.*
324 2022;9:944909.
- 325 17. Liang Y, Mao X, Kuang M, et al. Interleukin-6 affects the severity of olfactory
326 disorder: a cross-sectional survey of 148 patients who recovered from
327 Omicron infection using the Sniffin' Sticks test in Tianjin, China. *Int J Infect*
328 *Dis.* 2022;123:17–24.
- 329 18. Yang W, Yang S, Wang L, et al. Clinical characteristics of 310 SARS-CoV-2
330 Omicron variant patients and comparison with Delta and Beta variant patients
331 in China. *Viol Sin.* 2022;37(5):704–15.
- 332 19. Zhang H, Chen W, Ye X, et al. Clinical characteristics of patients infected with
333 novel coronavirus wild strain, Delta variant strain and Omicron variant strain
334 in Quanzhou: A real world study. *Exp Ther Med.* 2022;25(1):62.
- 335 20. Shen J, Wu L, Wang P, et al. Clinical characteristics and short-term recovery
336 of hyposmia in hospitalized non-severe COVID-19 patients with Omicron
337 variant in Shanghai, China. *Front Med.* 2022;9:1038938.
- 338 21. Green BG. Chemesthesis and the Chemical Senses as Components of a
339 “Chemofensor Complex.” *Chem Senses.* 2012;37(3):201–6.
- 340 22. Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ,
341 Sedaghat AR. Olfactory Dysfunction and Sinonasal Symptomatology in
342 COVID-19: Prevalence, Severity, Timing, and Associated Characteristics.
343 *Otolaryngol Neck Surg.* 2020;163(1):114–20.
- 344 23. Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding
345 Parosmia: An fMRI Study. *ORL.* 2019;81(4):185–92.
- 346 24. Epstein JB, Smutzer G, Doty RL. Understanding the impact of taste changes in
347 oncology care. *Support Care Cancer.* 2016;24(4):1917–31.
- 348 25. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical
349 power analysis program for the social, behavioral, and biomedical sciences.
350 *Behav Res Methods.* 2007;39(2):175–91.
- 351 26. Cecchetto C, Di Pizio A, Genovese F, et al. Assessing the extent and timing of

- 352 chemosensory impairments during COVID-19 pandemic. *Sci Rep.*
353 2021;11(1):17504.
- 354 27. Albayay J, Fontana L, Parma V, Zampini M. Chemosensory Dysfunction in
355 Long-Term COVID-19 Assessed by Self-Reported and Direct Psychophysical
356 Methods. *Life.* 2022;12(10):1487.
- 357 28. Song J, Jing Q, Zhu E, et al. Alterations in smell or taste in individuals
358 infected with SARS-CoV-2 during periods of Omicron variant dominance. *Int*
359 *J Infect Dis.* 2023;128:278–84.
- 360 29. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell
361 and Taste Dysfunction in Patients With COVID-19: A Systematic Review and
362 Meta-analysis. *Mayo Clin Proc.* 2020;95(8):1621–31.
- 363 30. Borsetto D, Hopkins C, Philips V, et al. Self-reported alteration of sense of
364 smell or taste in patients with COVID-19: a systematic review and meta-
365 analysis on 3563 patients. *Rhinology.* 2020;58(5):430–6.
- 366 31. Luers JC, Rokohl AC, Loreck N, et al. Olfactory and Gustatory Dysfunction in
367 Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis Off Publ Infect Dis*
368 *Soc Am.* 2020;71(16):2262–4.
- 369 32. Mercante G, Ferreli F, De Virgilio A, et al. Prevalence of Taste and Smell
370 Dysfunction in Coronavirus Disease 2019. *JAMA Otolaryngol-- Head Neck*
371 *Surg.* 2020;146(8):1–6.
- 372 33. Pellegrino R, Mainland JD, Kelly CE, Parker JK, Hummel T. Prevalence and
373 correlates of parosmia and phantosmia among smell disorders. *Chem Senses.*
374 2021;46:bjab046.
- 375 34. Boscolo Rizzo P, Tirelli G, Meloni P, et al. Coronavirus disease 2019
376 (COVID-19)-related smell and taste impairment with widespread diffusion
377 of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)
378 Omicron variant. *Int Forum Allergy Rhinol.* 2022;12(10):1273–81.
- 379 35. Al-Ani RM, Acharya D. Prevalence of Anosmia and Ageusia in Patients with
380 COVID-19 at a Primary Health Center, Doha, Qatar. *Indian J Otolaryngol*
381 *Head Neck Surg.* 2022;74(S2):2703–9.
- 382 36. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P,
383 Doty RL. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy*
384 *Rhinol.* 2020;10(8):944–50.

385
386 CORRESPONDING AUTHOR

387 Laiquan Zou

388 Chemical Senses and Mental Health Lab, Department of Psychology, School of
389 Public Health, Southern Medical University, Guangzhou, Guangdong, China

390 Tel.: +86-20-62789234


391 zoulq@smu.edu.cn;

392

393 FIGURES

394

395 **Figure 1** The results of self-rating of smell, taste, and chemesthesis function



396

397

398

399

*** $p < 0.001$.

400 TABLES

401 **Table 1 The prevalence of smell, taste, and chemesthesis disorders among**
402 **patients with COVID-19**

Variable	n	Total prevalence (N = 1245)	Prevalence in people with smell/taste/chemesthesis disorder
Smell disorder*	861	69.2%	\
Anosmia	290	23.3%	33.7%
Hyposmia	529	42.5%	61.4%
Parosmia	60	4.8%	7.0%
Phantosmia	98	7.9%	11.4%
Smell fluctuation	438	35.2%	50.9%
Taste disorder*	843	67.7%	\
Ageusia	236	19.0%	28.0%
Hypogeusia	499	40.1%	59.2%
Parageusia	282	22.7%	33.5%
Phantogeusia	333	26.7%	39.5%
Chemesthesis disorder	391	31.4%	\
Complete loss	35	2.8%	9.0%
Partial loss	356	28.6%	91.0%

403 *Multiple responses

404

405 **Table 2 Association between smell disorder and demographic/COVID-19-related**
 406 **characteristics among patients**

Variable	Smell disorder (%)		Total (%)	p value
	Yes (n = 861)	No (n = 384)	N = 1245	
Sex				
Male	170 (19.7)	92 (24.0)	262 (21.0)	0.092
Female	691 (80.3)	292 (76.0)	983 (79.0)	
Age, years				
18–29	702 (81.5)	327 (85.2)	1029 (82.7)	0.204
30–39	116 (13.5)	38 (9.9)	154 (12.4)	
40–49	30 (3.5)	16 (4.2)	46 (3.7)	
≥ 50	13 (1.5)	3 (0.8)	16 (1.3)	
Smoking				
Current	32 (3.7)	5 (1.3)	37 (3.0)	0.012
Former	38 (4.4)	9 (2.3)	47 (3.8)	
Never	791 (91.9)	370 (96.4)	1161 (93.3)	
Alcohol				
Yes	441 (51.2)	184 (47.9)	625 (50.2)	0.282
No	420 (48.8)	200 (52.1)	620 (49.8)	
Chronic rhinitis				
Yes	137 (15.9)	48 (12.5)	185 (14.9)	0.118
No	724 (84.1)	336 (87.5)	1060 (85.1)	
Allergic rhinitis				
Yes	208 (24.2)	91 (23.7)	299 (24.0)	0.861
No	653 (75.8)	293 (76.3)	946 (76.0)	
Any comorbidity or special condition[#]				
Yes	106 (12.3)	42 (10.9)	148 (11.9)	0.489
No	755 (87.7)	342 (89.1)	1097 (88.1)	
Method of diagnosis				
PCR test	134 (15.6)	67 (17.4)	201 (16.1)	0.706
Antigen test	459 (53.3)	200 (52.1)	659 (52.9)	
Symptoms	268 (31.1)	117 (30.5)	385 (30.9)	
Rehabilitation status				
Complete	283 (32.9)	167 (43.5)	450 (36.1)	< 0.001
Partial	578 (67.1)	217 (56.5)	795 (63.9)	
Symptoms[*]				
Fever	818 (95.0)	358 (93.2)	1176 (94.5)	0.206
Lack of appetite	547 (63.5)	168 (43.8)	715 (57.4)	< 0.001
Dry and sore throat	692 (80.4)	284 (74.0)	976 (78.4)	0.011
Myalgia	604 (70.2)	240 (62.5)	844 (67.8)	0.008
Headache	598 (69.5)	256 (66.7)	854 (68.6)	0.328
Diarrhea	191 (22.2)	71 (18.5)	262 (21.0)	0.140
Cough/expectoration	747 (86.8)	321 (83.6)	1068 (85.8)	0.140
Stuffy/running nose	704 (81.8)	281 (73.2)	985 (79.1)	0.001
Dyspnea	158 (18.4)	43 (11.2)	201 (16.1)	0.002
Fatigue	602 (69.9)	232 (60.4)	834 (67.0)	0.001

COVID-19 vaccination

Yes (n = 1208)	828 (96.2)	380 (99.0)	1208 (97.0)	0.007
No (n = 37)	33 (3.8)	4 (1.0)	37 (3.0)	

407 #Comorbidity or special condition includes hypertension, diabetes, cardiovascular
408 disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic
409 kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial
410 asthma, mental illness, and in the third trimester of pregnancy or perinatal period.
411 *Multiple responses
412

413 **Table 3 Association between taste disorder and demographic/COVID-19-related**
 414 **characteristics among patients**

Variable	Taste disorder (%)		Total (%)	p value
	Yes (n = 843)	No (n = 402)	Yes (n = 1245)	
Sex				
Male	167 (19.8)	95 (23.6)	262 (21.0)	0.122
Female	676 (80.2)	307 (76.4)	983 (79.0)	
Age, years				
18–29	687 (81.5)	342 (85.1)	1029 (82.7)	0.430
30–39	113 (13.4)	41 (10.2)	154 (12.4)	
40–49	32 (3.8)	14 (3.5)	46 (3.7)	
≥ 50	11 (1.3)	5 (1.2)	16 (1.3)	
Smoking				
Current	27 (3.2)	10 (2.5)	37 (3.0)	0.194
Former	37 (4.4)	10 (2.5)	47 (3.8)	
Never	779 (92.4)	382 (95.0)	1161 (93.3)	
Alcohol				
Yes	430 (51.0)	195 (48.5)	625 (50.2)	0.409
No	413 (49.0)	207 (51.5)	620 (49.8)	
Chronic rhinitis				
Yes	129 (15.3)	56 (13.9)	185 (14.9)	0.524
No	714 (84.7)	346 (86.1)	1060 (85.1)	
Allergic rhinitis				
Yes	206 (24.4)	93 (23.1)	299 (24.0)	0.615
No	637 (75.6)	309 (76.9)	946 (76.0)	
Any comorbidity or special condition[#]				
Yes	109 (12.9)	39 (9.7)	148 (11.9)	0.100
No	734 (87.1)	363 (90.3)	1097 (88.1)	
Method of diagnosis				
PCR test	135 (16.0)	66 (16.4)	201 (16.1)	0.466
Antigen test	438 (52.0)	221 (55.0)	659 (52.9)	
Symptoms	270 (32.0)	115 (28.6)	385 (30.9)	
Rehabilitation status				
Complete	292 (34.6)	158 (39.3)	450 (36.1)	0.109
Partial	551 (65.4)	244 (60.7)	795 (63.9)	
Symptoms[*]				
Fever	800 (94.9)	376 (93.5)	1176 (94.5)	0.324
Lack of appetite	554 (65.7)	161 (40.0)	715 (57.4)	< 0.001
Dry and sore throat	677 (80.3)	299 (74.4)	976 (78.4)	0.017
Myalgia	591 (70.1)	253 (62.9)	844 (67.8)	0.011
Headache	599 (71.1)	255 (63.4)	854 (68.6)	0.007
Diarrhea	196 (23.3)	66 (16.4)	262 (21.0)	0.006
Cough/expectoration	739 (87.7)	329 (81.8)	1068 (85.8)	0.006
Stuffiness/runny nose	681 (80.8)	304 (75.6)	985 (79.1)	0.036
Dyspnea	158 (18.7)	43 (10.7)	201 (16.1)	< 0.001
Fatigue	598 (70.9)	236 (58.7)	834 (67.0)	< 0.001

COVID-19 vaccination

Yes	814 (96.6)	394 (98.0)	1208 (97.0)	0.159
No	29 (3.4)	8 (2.0)	37 (3.0)	

415 #Comorbidity or special conditions included hypertension, diabetes, cardiovascular
416 disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic
417 kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial
418 asthma, mental illness, and in the third trimester of pregnancy or perinatal period.

419 *Multiple responses.

420

421 **Table 4 Association between chemesthesis disorder and patient demographic**
 422 **characteristics**

Variable	Chemesthesis disorder (%)		Total (%)	p value
	Yes (n = 391)	No (n = 854)	Yes (n = 1245)	
Sex				
Male	70 (17.9)	192 (22.5)	262 (21.0)	0.066
Female	321 (82.1)	662 (77.5)	983 (79.0)	
Age, years				
18–29	310 (79.3)	719 (84.2)	1029 (82.7)	0.160
30–39	60 (15.3)	94 (11.0)	154 (12.4)	
40–49	15 (3.8)	31 (3.6)	46 (3.7)	
≥ 50	6 (1.5)	10 (1.2)	16 (1.3)	
Smoking				
Current	12 (3.1)	25 (2.9)	37 (3.0)	0.914
Former	16 (4.1)	31 (3.6)	47 (3.8)	
Never	363 (92.8)	798 (93.4)	1161 (93.3)	
Alcohol				
Yes	203 (51.9)	422 (49.4)	625 (50.2)	0.412
No	188 (48.1)	432 (50.6)	620 (49.8)	
Chronic rhinitis				
Yes	62 (15.9)	123 (14.4)	185 (14.9)	0.503
No	329 (84.1)	731 (85.6)	1060 (85.1)	
Allergic rhinitis				
Yes	86 (22.0)	213 (24.9)	299 (24.0)	0.259
No	305 (78.0)	641 (75.1)	946 (76.0)	
Any comorbidity or special condition[#]				
Yes	49 (12.5)	99 (11.6)	148 (11.9)	0.635
No	342 (87.5)	755 (88.4)	1097 (88.1)	
Method of diagnosis				
PCR test	60 (15.3)	141 (16.5)	201 (16.1)	0.693
Antigen test	204 (52.2)	455 (53.3)	659 (52.9)	
Symptoms	127 (32.5)	258 (30.2)	385 (30.9)	
Rehabilitation status				
Complete	126 (32.2)	324 (37.9)	450 (36.1)	0.051
Partial	265 (67.8)	530 (62.1)	795 (63.9)	
Symptoms[*]				
Fever	369 (94.4)	807 (94.5)	1176 (94.5)	0.930
Lack of appetite	261 (66.8)	454 (53.2)	715 (57.4)	< 0.001
Dry and sore throat	312 (79.8)	664 (77.8)	976 (78.4)	0.416
Myalgia	270 (69.1)	574 (67.2)	844 (67.8)	0.519
Headache	266 (68.0)	588 (68.9)	854 (68.6)	0.772
Diarrhea	84 (21.5)	178 (20.8)	262 (21.0)	0.797
Cough/expectoration	341 (87.2)	727 (85.1)	1068 (85.8)	0.329
Stuffy/running nose	309 (79.0)	676 (79.2)	985 (79.1)	0.959
Dyspnea	87 (22.3)	114 (13.3)	201 (16.1)	< 0.001
Fatigue	284 (72.6)	550 (64.4)	834 (67.0)	0.004

COVID-19 vaccination

Yes	374 (95.7)	834 (97.7)	1208 (97.0)	0.053
No	17 (4.3)	20 (2.3)	37 (3.0)	

423 #Comorbidity or special conditions included hypertension, diabetes, cardiovascular
424 disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic
425 kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial
426 asthma, mental illness, and in the third trimester of pregnancy or perinatal period.
427 *Multiple response.
428